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Hodgkin lymphoma is a cancer that can 
be cured using standard chemotherapy with or 
without radiation. Although it accounts for only 
0.6% of all malignancy worldwide, but it usually 
affects young adults with median age of 38 years. 
About 60 to 90% cases can be cured depending 
on its stage and 5 to 10% cases are refractory 
to the first-line chemotherapy; while 20 to 30% 
patients experiencing relapse after receiving the 
first-line chemotherapy.1 The relapse causes new 
problem in treatment. A monoclonal antibody-
chemotherapy conjugate, Brentuximab vedotin, 
was approved by Food Drug Association and 
European Medicine since 2011 dan was approved 
by European Medicine Agency since 2012 to 
treat relapsed classical Hodgkin lymphoma 
and anaplastic large cell lymphoma (ALCL). 
Brentuximab vedotin has also been known as 
anti-CD30.2
CD30 or Ki-1 or TNFRSF8 is a 120-kD 
glycoprotein, which is a trans-membrane receptor 
of Hodgkin lymphoma cells. The glycoprotein 
was first identified in 1982 using monoclonal 
antibody against Hodgkin lymphoma-derived 
cell lines. The glycoprotein was then cloned 
and recognized as a member of tumor necrosis 
factor receptor (TNFR) superfamily, which 
has intracellular, transcellular and extracellular 
domains.3,4 The monoclonal antibody obviously 
does cause a reaction not only with the Reed-
Sternberg (RS) cells of Hodgkin lymphoma, but 
also with a small number of normal lymphocytes 
subset, which are located at perifollicular zone 
as well as lymphoid tumor such as anaplastic 
large cell lymphoma (ALCL) and other non-
lymphoid tumor such as embryonic and pancreas 
carcinoma, undifferentiated nasopharyngeal 
carcinoma and malignant melanoma. Therefore, 
CD30 monoclonal antibody alone to confirm the 
diagnosis of Hodgkin lymphoma is ineffective 
as it must be used together with other panel 
of immunohistochemistry antibodies such as 
cytokeratins, carcinoma embryonic antigen, 
melanoma-associated antigen and placental 
alkaline phosphatide.5,6
The expression of CD30 molecules in Reed-
Sternberg cells of Hodgkin lymphoma has been 
demonstrated in over 98% of classical Hodgkin 
lymphoma cases; however, there is a difference 
in staining intensity among various cases or even 
in one case.6
In addition to the CD30, CD15 is also a 
very important marker for Hodgkin lymphoma / 
Reed-Sternberg (RS) cells and it is found in more 
than 80% of classical Hodgkin lymphoma cases. 
CD15 is a typical antigen for classical Hodgkin 
lymphoma; however, it is not specific as it is also 
found in T-cell and B-cell lymphoma as well as 
non-lymphoid tumor.6
The National Comprehensive Cancer 
Network (NCCN) and European Society Medical 
Oncology (ESMO) have recommended the test of 
both antigens for cases with suspected classical 
Hodgkin lymphoma.7,8 A study by Fadhil et al9 in 
Northern Iraq with 42 cases of classical Hodgkin 
lymphoma has demonstrated that 100% cases 
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have CD30 expression and only 51.8% cases 
have CD15 expression. A study in Indonesia 
by Ranuhardi et al, which is published in the 
present edition, has successfully demonstrated 
CD30 expression in 88.9% cases and CD15 
expression in 37.5% cases of the studied 42 
Hodgkin lymphoma cases. The study results 
indicate that Indonesia is ready to follow the 
current standard treatment guideline for relapsed 
classical Hodgkin lymphoma, which requires 
immunohistochemistry examination of CD30 
as the target therapy of Brentuximab vedotin 
treatment along with the approval that has been 
issued by Indonesian National Agency of Drug 
and Food Control (NADFC) in late 2007.
Brentuximab vedotin acts by binding 
with the CD30 receptor at the surface of 
Hodgkin lymphoma/Reed-Sternberg cells, which 
then performs internalization with lysosome. 
Afterward, monomethyl auristatin E (MMAE) 
is released into proliferated tubulin cells and the 
apoptosis of Reed-Sternberg cells takes place.
Over-expression of CD30 is actually not only 
found in lymphoid and non-lymphoid malignant 
cases. It is also found in T lymphocytes of 
patients with systemic lupus erythematosus 
(SLE) particularly in CD8 of the T lymphocytes. 
There are ongoing clinical trials on the use of 
anti-CD30 for SLE. Moreover, the 88-kD soluble 
CD30 (sCD30), which is found in inflammatory 
condition is also associated with the activity of 
SLE disease.10
Shooshtarizadeh et al show that the high level 
sCD30 prior to transplantation is a risk factor for 
rejected renal transplantation.11 Moreover, Susal 
et al also demonstrate that the high level of sCD30 
prior to transplantation may have more significant 
implication on treatment of rejection after one-
year renal transplantation and the risk of losing the 
graft is higher on 5-year follow up.12 In Indonesia, 
Bonar et al provide a report in this edition that the 
one-year survival of graft and patients are 92% 
and 87%; while the 3-year survival are 90.6% and 
79.7%. Amirzagar et al.13 showed that the high 
level of sCD30 prior to renal transplantation and 
the 1 week and 2 weeks post-transplantation is 
associated with poor graft survival.
In addition to malignancy and autoimmune 
cases, increased expression of CD30 is also 
found in allergy cases such as asthma. Rojas et 
al14 demonstrated that there was increased CD30 
expression of Th2 lymphocytes in children with 
atopic asthma. Meanwhile, Polte et al15 showed 
the role of interaction between CD30 receptor and 
its ligand (CD153) in inducing allergic asthma 
facilitated by Th2 cells. Foks et al16 suggested 
that there is a role of interaction between 
CD30 and CD30 ligand in the development of 
atherosclerosis. In their study, Foks et al gave 
antibody against CD30 ligand in mice that 
interrupted the interaction between CD30 and 
CD30 ligand, which then diminishing the initial 
development of atherosclerosis.
CD30, CD30 ligand and sCD30 have roles 
in the pathogenesis of malignant, autoimmune, 
allergy and metabolic disease. The three of them 
can be diagnostic, prognostic or therapeutic 
marker for classical Hodgkin lymphoma, 
cardiovascular disease, lupus erythematosus, 
asthma and allergy.
Bretuximab vedotin, which is the novel anti-
CD30 has been recently approved as treatment 
for Hodgkin lymphoma and is still studied in 
ongoing clinical trials as treatment for systemic 
lupus erythematosus.17 It provides evidences of 
interconnection between basic medical science 
and clinical medicine in medical advance. 
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